title: [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
abstract: Twenty patients with refractory malignant lymphoma were treated with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) as salvage chemotherapy. These patients were either resistant to front-line therapy or refractory in their relapses. Two patients (10%) achieved a complete remission and eleven patients (55%) attained a partial remission. An overall response rate was 65%. Major toxicities were myelosuppression, nausea and vomiting, and mucositis. However they were well tolerated. This regimen has been effective in the treatment for the patients with refractory lymphoma.
authors: K
authors: K
authors: Ohnishi
authors: T
authors: T
authors: Hotta
authors: T
authors: T
authors: Murate
authors: C
authors: C
authors: Inoue
authors: A
authors: A
authors: Ichikawa
authors: N
authors: N
authors: Ninomiya
authors: S
authors: S
authors: Goto
authors: K
authors: K
authors: Tsushita
authors: M
authors: M
authors: Utsumi
authors: E
authors: E
authors: Nagura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D005047:Etoposide; D011239:Prednisolone; D007069:Ifosfamide; D008727:Methotrexate